EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 1100-1109

  Bradley, Amber ^a   Zheng, Hui ^a   Ziebarth, Angela ^b   Sakati, Wayne ^a   Branham O'connor, Melissa ^a   Blumer, Joe B ^a   Liu, Yuying ^a   Kistner Griffin, Emily ^a,c   Rodriguez Aguayo, Cristian ^d   Lopez Berestein, Gabriel ^d   Sood, Anil K ^d   Landen, Charles N ^b   Eblen, Scott T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN MCL 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; COS 7 CELL LINE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEOLYSIS; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901986176     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt489     Document Type: Article

References (47)

1. O'Brien, P.M. et al. (2008) The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br. J. Cancer, 98, 1085-1093.
2. Henderson, M.J. et al. (2002) EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J. Biol. Chem., 277, 26468-26478.
3. Bethard, J.R. et al. (2011) Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD. J. Proteomics, 75, 603-609.
4. Eblen, S.T. et al. (2003) Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J. Biol. Chem., 278, 14926-14935.
5. Rechsteiner, M. et al. (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol., 15, 27-33.
6. Wolf, D.H. et al. (2004) The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim. Biophys. Acta, 1695, 19-31.
7. Callaghan, M.J. et al. (1998) Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs. Oncogene, 17, 3479-3491.
8. Munoz, M.A. et al. (2007) The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle, 6, 3070-3077.
9. Gudjonsson, T. et al. (2012) TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes. Cell, 150, 697-709.
10. Henderson, M.J. et al. (2006) EDD mediates DNA damage-induced activation of CHK2. J. Biol. Chem., 281, 39990-40000.
11. Clancy, J.L. et al. (2003) EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene, 22, 5070-5081.
12. Fuja, T.J. et al. (2004) Somatic mutations and altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal carcinoma. Cancer Res., 64, 942-951.
13. Mori, Y. et al. (2002) Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res., 62, 3641-3645.
14. Wasenius, V.M. et al. (1997) Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer, 18, 286-291.
15. Eblen, S.T. et al. (2001) Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Mol. Cell. Biol., 21, 249-259.
16. Chao, J.R. et al. (1998) mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol. Cell. Biol., 18, 4883-4898.
17. Landen, C.N. Jr et al. (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res., 65, 6910-6918.
18. Landen, C.N. et al. (2006) Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol. Ther., 5, 1708-1713.
19. Ola, M.S. et al. (2011) Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol. Cell. Biochem., 351, 41-58.
20. Burlacu, A. (2003) Regulation of apoptosis by Bcl-2 family proteins. J. Cell. Mol. Med., 7, 249-257.
21. Hadji, A. et al. (2010) Caspase-3 triggers a TPCK-sensitive protease pathway leading to degradation of the BH3-only protein puma. Apoptosis, 15, 1529-1539.
22. Ding, Q. et al. (2007) Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol., 27, 4006-4017.
23. Hay-Koren, A. et al. (2011) The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin. Mol. Biol. Cell, 22, 399-411.
24. Martinez, A. et al. (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 45, 1292-1299.
25. Klein, P.S. et al. (1996) A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. U. S. A., 93, 8455-8459.
26. Phiel, C.J. et al. (2001) Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol., 41, 789-813.
27. Kaidanovich-Beilin, O. et al. (2006) Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther., 316, 17-24.
28. Rao, R. et al. (2007) Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia, 50, 452-460.
29. Landen, C.N. et al. (2005) EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets, 9, 1179-1187.
30. Halder, J. et al. (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res., 12, 4916-4924.
31. Merritt, W.M. et al. (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl Cancer Inst., 100, 359-372.
32. Lin, Y.G. et al. (2008) Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin. Cancer Res., 14, 5437-5446.
33. Mangala, L.S. et al. (2009) Liposomal siRNA for ovarian cancer. Methods Mol. Biol., 555, 29-42.
34. Nick, A.M. et al. (2011) Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J. Natl Cancer Inst., 103, 1596-1612.
35. Chakravarty, D. et al. (2011) Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin. Cancer Res., 17, 2250-2259.
36. Shigemasa, K. et al. (2002) Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn. J. Cancer Res., 93, 542-550.
37. Brotin, E. et al. (2010) Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int. J. Cancer, 126, 885-895.
38. Simonin, K. et al. (2009) Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol. Cancer Ther., 8, 3162-3170.
39. Iqbal, S. et al. (2012) PDGF upregulates Mcl-1 through activation of ß-catenin and HIF-1a-dependent signaling in human prostate cancer cells. PLoS One, 7, e30764.
40. Croxton, R. et al. (2002) Direct repression of the Mcl-1 promoter by E2F1. Oncogene, 21, 1359-1369.
41. Croxton, R. et al. (2002) Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter. Oncogene, 21, 1563-1570.
42. Magklara, A. et al. (2009) A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. Mol. Endocrinol., 23, 61-73.
43. Saran, U. et al. (2012) Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell Biol., 13, 25.
44. Matsumura, N. et al. (2011) Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res., 21, 74-82.
45. Ye, G. et al. (2011) MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J. Cell Sci., 124, 359-368.
46. Smith, J.A. et al. (2005) An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol. Oncol., 98, 141-145.
47. Galluzzi, L. et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene, 31, 1869-1883.